Primary Mediastinal B‐Cell Lymphoma in Clinical Practice: A Case‐Based Approach to Unresolved Diagnostic and Therapeutic Dilemmas
Hematological Oncology · 2026-11 · 44 (6)
DOI: 10.1002/hon.70296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 22.11.2026. Verfasst von Sarah Bailly und 14 weiteren Autor:innen. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Primary mediastinal B‐cell lymphoma (PMBL) is a rare and biologically distinct subtype of aggressive B‐cell lymphoma that predominantly affects young adults. Despite substantial therapeutic advances, several aspects of its management remain controversial, including frontline treatment selection, the role of radiotherapy, PET‐based response assessment, and the optimal sequencing of immunotherapies in relapsed disease. Drawing on prospective and retrospective studies, cooperative group data, expert consensus and our own real‐world experience, we present a practical case‐based approach across the disease course, built around four clinical cases followed to their resolution and covering diagnosis, frontline treatment, PET‐guided response assessment, pregnancy‐associated disease, adolescents and young adults, relapsed or refractory disease, and long‐term follow‐up. We focus on decision‐making where evidence remains limited, including the integration of immune checkpoint inhibitors (ICIs), CAR‐T cell therapy, radiotherapy and transplantation, and the emerging role of circulating tumor DNA (ctDNA) and radiomics. Management increasingly relies on individualized, multidisciplinary decision‐making that integrates disease biology, functional imaging and patient characteristics to maximize cure while minimizing long‐term toxicity. In our practice this translates into dose‐intensified frontline chemoimmunotherapy rather than R‐CHOP21, omission of radiotherapy after a complete metabolic response and, where these treatments are accessible, a second‐line strategy built on checkpoint inhibitors and anti‐CD19 CAR‐T cells, with early referral for cellular therapy in refractory or early relapse.
Zitieren
APA
Bailly, S., Noël, R., Galtier, J., Renaud, L., Decroocq, J., Kirova, Y., Traverse‐Glehen, A., Donzel, M., Bailly, S., Sesques, P., Minard‐Colin, V., Gheysens, O., Neste, E. V. D., Constantinescu, S. N., & Camus, V. (2026). Primary Mediastinal B‐Cell Lymphoma in Clinical Practice: A Case‐Based Approach to Unresolved Diagnostic and Therapeutic Dilemmas. Hematological Oncology, 44(6). https://doi.org/10.1002/hon.70296
Vancouver
Bailly S, Noël R, Galtier J, Renaud L, Decroocq J, Kirova Y, et al. Primary Mediastinal B‐Cell Lymphoma in Clinical Practice: A Case‐Based Approach to Unresolved Diagnostic and Therapeutic Dilemmas. Hematological Oncology. 2026;44(6). doi:10.1002/hon.70296
BibTeX
@article{Bailly2026,
author = {Bailly, Sarah and Noël, Robin and Galtier, Jean and Renaud, Loïc and Decroocq, Justine and Kirova, Youlia and Traverse‐Glehen, Alexandra and Donzel, Marie and Bailly, Sébastien and Sesques, Pierre and Minard‐Colin, Véronique and Gheysens, Olivier and Neste, Eric Van Den and Constantinescu, Stefan N. and Camus, Vincent},
title = {Primary Mediastinal B‐Cell Lymphoma in Clinical Practice: A Case‐Based Approach to Unresolved Diagnostic and Therapeutic Dilemmas},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {6},
doi = {10.1002/hon.70296}
}
EUVIMED